Recombinant Human LILRA2/CD85h/ILT1 Protein, CF Summary
Product Specifications
Gly24-Asn449, with a C-terminal 6-His tag
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
9040-T4
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
| Reconstitution | Reconstitute at 500 μg/mL in PBS. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Scientific Data
View Larger
When Recombinant Human LILRA2/CD85h/ILT1 (Catalog # 9040-T4) is coated at 2 µg/mL, Recombinant Human Angiopoietin-like 7 Protein (Catalog # 914-AN) binds with a typical ED50 of 150-900 ng/mL.
Reconstitution Calculator
Background: LILRA2/CD85h/ILT1
LILRA2, also known as ILT1, CD85h, and LIR7, is an approximately 70 kDa variably glycosylated transmembrane protein that regulates immune cell activation (1). Mature human LILRA2 consists of a 426 amino acid (aa) extracellular domain (ECD) with 4 Ig-like domains, a 21 aa transmembrane segment, and a 13 aa cytoplasmic tail (2). Alternative splicing generates isoforms with short deletions between the fourth Ig-like domain and the transmembrane region, and an isoform that is truncated C-terminal to the fourth Ig-like domain (3, 4). LILRA2 is expressed on monocytes, neutrophils, basophils, and eosinophils (5-7). It contains a positively charged arginine residue in its transmembrane segment, enabling association with the signaling protein Fc epsilon RI gamma (5). Cross-linking of LILRA2 on monocytes induces the production of multiple cytokines as well as the upregulation of Fc gamma receptors (6, 7). Cross-linking also restricts monocyte differentiation into immature dendritic cells, phagocytic activity, and antigen presentation to T cells (6, 7). R&D Systems in-house testing indicates that LILRA2 binds to Angiopoietin-like 7, consistent with the demonstrated functional interactions between other members of these protein families.
- Thomas, R. et al. (2010) Clin. Rev. Allergy Immunol. 38:159.
- Borges, L. et al. (1997) J. Immunol. 159:5192.
- Jones, D.C. et al. (2009) Eur. J. Immunol. 39:3195.
- Mamegano, K. et al. (2008) Genes Immun. 9:214.
- Nakajima, H. et al. (1999) J. Immunol. 162:5.
- Lu, H.K. et al. (2012) PLoS One 7:e33478.
- Lee, D.J. et al. (2007) J. Immunol. 179:8128.
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Human LILRA2/CD85h/ILT1 Protein, CF
Average Rating: 5 (Based on 1 Review)
Have you used Recombinant Human LILRA2/CD85h/ILT1 Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
Reason for Rating: good material
Performed binding specificity experiments for the lead molecule (xLILRA6) on its ligand family panels (RA1, RA2, RA5, RA6, RB1, RB2, RB3, RB4, RB5)
